Afatinib Efficacious in EGFR+ NSCLC Harboring Major Uncommon Mutations, Irrespective of Ethnicity
posted 2 days
Mashup Score: 4
OncLive - Afatinib was found to be effective when used in Asian and non-Asian patients with non–small cell lung cancer with major uncommon and compound EGFR...
NICE Recommends Isatuximab Plus Pomalidomide/Dexamethasone for Relapsed/Refractory Myeloma
posted 1 day
Mashup Score: 3
OncLive - The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for...
OncLive - Igor I. Rybkin, MD, PhD, discusses the data with these frontline and second-line regimens in extensive-stage small cell lung...
OncLive - The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions...
Fight Cancer using your own T-Cells
posted 2 months
Despite recent advancements in immuno-oncology, not all patients with cancer benefit from current treatments, and additional therapeutic options are needed for both hematologic malignancies...
OncLive - Mentoring is critically important to the development of young academic hematology/oncology...
Nivolumab Nears EU Approval for Second-Line Esophageal Squamous Cell Carcinoma
posted 17 hours
Mashup Score: 1
OncLive - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for nivolumab in the treatment of adult patients...
studio.mjhassoc.com - This live broadcast will be presented by OncLive® and hosted by Karyopharm® Therapeutics. Please use the event date dropdown below to select one of...
FDA Grants Priority Review to Adjuvant Osimertinib for Early-Stage EGFR+ Lung Cancer
posted 38 mins
Mashup Score: 1
OncLive - The FDA has granted osimertinib a priority review designation to a supplemental new drug application for the adjuvant treatment of patients with early-stage EGFR-mutated...
interactive-tools.onclive.com - INDICATIONXPOVIO® (selinexor) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL...
Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC
posted 12 hours
Mashup Score: 1
OncLive - Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of...
Afatinib Efficacious in EGFR+ NSCLC Harboring Major Uncommon Mutations, Irrespective of Ethnicity @IASLC #lcsm #NSCLC20 https://t.co/4qsWrdFG2x